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Background
Well-functioning civil registration and vital statistics
(CRVS) systems provide policymakers and stakeholders
with accurate and timely information regarding the
number of births, deaths, and specific causes of mortality
within a population. Ideally, this information is used to
guide the effective delivery of health and social develop-
ment programs [1]. These systems can also facilitate ef-
forts to promote equity and justice by demonstrating the
needs of the poorest and most vulnerable groups.
However, many low and middle-income countries
(LMICs) – those with the greatest potential benefit from
such information – depend on facility-based systems
that generate data only on the subset of the population
that reaches a health facility [2]. In Uganda, for example,
recent national surveys suggest that less than one-third
of children under 5 years of age, and less than one-
quarter of deaths, are registered with civil authorities,
with the lowest rates seen among poor and rural respon-
dents. Failing to capture these vital events creates an “in-
visible population,” which exacerbates already stark
divides between rich and poor, urban and rural [3].
While civil registration with high and representative
coverage remains the long-term goal, investment in
complementary approaches is urgently needed. This will
not only accelerate the design, implementation, and
evaluation of cost-effective interventions, but also help
to achieve the Sustainable Development Goal (SDG) of
100% birth and 80% death registration [2, 4, 5]. Verbal
autopsies (VA), which involve interviews with next of
kin or caregivers of the deceased, have been adopted as
a practical means of determining the cause of death in
areas where CRVS systems are weak [6, 7]. While imper-
fect, there is ample evidence that VA-based algorithms
yield cause of death estimates comparable to other
methods [8, 9].
How good is “good enough?”
The article by Hazard et al. [10] describes the implemen-
tation and scale-up of SmartVA, an automated verbal
autopsy data collection tool, across multiple countries
and contexts. The effort required to roll out this ambi-
tious program, which is supported by Bloomberg Philan-
thropies’ Data for Health (D4H) Initiative, represents a
sizeable achievement in itself and we should not over-
look its potential impact on long-term public health.
The authors report estimated cause-specific mortality
fractions (CSMF) derived from more than 55,000
events, occurring in four countries analyzed using the
SmartVA-Analyze tool. Myanmar and Bangladesh ac-
count for about 90% of deaths. It should be highlighted
that most of these events would have not otherwise
been captured by existing CRVS systems. Had these
deaths been documented, many would have not been
assigned a cause of death, let alone an accurate one.
These results thus represent a major step towards
achieving both the SDG targets, as well as more equit-
able representation in routine data.
Operational successes aside, these findings raise some
important questions. For example, what is the appropri-
ate comparator, if any, that we should be using to valid-
ate and monitor VA-based CRVS systems? Undoubtedly,
the data produced by VA is better than that which
existed prior to implementation (i.e. no data), but is this
good enough? In the short-term, the answer is probably
“yes.” For many areas of the world, simply having access
to rigorously collected and systematically analyzed data,
even if imperfect, may accelerate the delivery of needed
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services, advance the effective allocation of limited re-
sources, and help to engage poor and rural communities
in policymaking. Over the longer term, however, the an-
swer is less clear and highly context-dependent. VA-
based interventions are still considered a stop-gap meas-
ure, filling a void until more rigorous, traditional CRVS
systems are established. Identifying the time points at
which transition from VA-based to traditional CRVS
systems should occur will be a key challenge.
In the interim, what should be done when VA analysis
is unable to determine a cause of death, such as in ap-
proximately 18% of events recorded in Myanmar and
Pakistan? Here, the SmartVA-Analyze software redistrib-
uted these deaths based on demographic covariates and
country-specific patterns of mortality, derived from the
Global Burden of Disease (GBD) study. This approach
likely biases the results towards the comparator, which –
in this case – is the very same GBD study. As the au-
thors note, the comparison was not intended for valid-
ation, but rather as a convenient (and perhaps the only
available) measure of plausibility.
Should we, however, redistribute deaths at all?
While the GBD study data probably represents the
best available data to inform redistribution, its uncer-
tainty is likely to be greatest in the places where VA-
based CRVS systems are most needed. Notably, in
Papua New Guinea and the Philippines, there were
fewer deaths with unknown cause (6 and 5%, respect-
ively), and the results of the VA analysis differed in
important ways from the GBD estimates. Therefore,
are we doing a disservice to poor and rural popula-
tions by assigning attribution to their deaths using
data that is more likely to be derived from popula-
tions with more resources and better access to care?
Is this just another form of invisibility, albeit occur-
ring in a much smaller proportion of deaths than be-
fore? Ideally, deaths of underdetermined cause should
prompt further investigation, especially if clustered in
space or time. These deaths might be prioritized for
physician review, as was done in the Philippines, as a
means of more effectively applying limited resources.
Conclusions
The findings presented in this article provide further evi-
dence that implementation of VA-based tools to aug-
ment CRVS systems in LMICs is feasible, acceptable,
and effective. Context-specific experience should guide
iterative development and refinement of data collection
software, protocols, and analysis algorithms, with par-
ticular attention being paid to addressing unknown
causes of death. However, this should not delay the im-
plementation of an evidence-based strategy to overcome
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